BioXcel Therapeutics Reports Positive Human Proof-of-Concept Data for Acute Treatment of Agitation in Patients with Alzheimer’s Disease Jan 3, 2019
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL501 for Acute Treatment of Agitation Dec 27, 2018
BioXcel Therapeutics Doses First Subjects in Pharmacokinetic (Bioavailability) and Safety Study of BXCL501 for the Acute Treatment of Agitation Dec 19, 2018
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Neuroscience Candidate, BXCL501 for the Acute Treatment of Agitation Dec 12, 2018
BioXcel Therapeutics to Present at BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference Dec 3, 2018
BioXcel Therapeutics Reports Positive Results from Study in Agitated Schizophrenia Patients Supporting BXCL501 Clinical Development Nov 14, 2018
BioXcel Therapeutics Reports Third Quarter 2018 Quarterly Results and Provides Business Update Nov 9, 2018
BioXcel Therapeutics Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, BXCL701, in Treatment Emergent Neuroendocrine Prostate Cancer Nov 5, 2018
BioXcel Therapeutics to Host Third Quarter 2018 Financial Results and Business Update Conference Call Nov 2, 2018
BioXcel Therapeutics Announces Presentation on Functional Immunological Memory Formation Across Diverse Tumor Types at the SITC 2018 Annual Meeting Oct 31, 2018
